

Amendments to the Claims

91. (Currently Amended) A method for preventing or inhibiting inflammatory disease in a patient in need thereof, comprising the administration of an effective amount of a ~~PTEN agonist~~ PI-3 kinase inhibitor selected from the group consisting of LY294002 and Wortmannin, said method further comprising the step of assessing immunoreceptor signaling following administration of said inhibitor.

92. (Original) The method as claimed in claim 91, wherein said inflammatory disease is selected from the group consisting of macular degeneration, arthritis, asthma, hay fever, systemic lupus erythematosis, Crohn's disease, and inflammatory bowel disease.

93. (Cancelled)

94. (Currently Amended) The method as claimed in claim 93 91, wherein said PI-kinase inhibitor is LY294002.

95. (Currently Amended) The method as claimed in claim 91, ~~further comprising the administration of an AKT inhibitor~~ wherein said PI-3 kinase inhibitor is Wortmannin.

96. (Cancelled)

97. (Currently amended) The method as claimed in claim [[96]] 91, wherein said immunoreceptor is selected from the group consisting of a T cell receptor, a B cell receptor, an ~~ITAM-bearing receptor~~, a Fc γ receptor, a FC ϵ RI receptor,

and a Fc α RI receptor.

98. (Currently amended) The method as claimed in claim [[96]] 91, wherein said inhibitor agonist inhibits Fc γ receptor mediated phagocytosis.

99. (Cancelled)

100. (Cancelled)

101. (Currently amended) The method of claim 91 wherein said inhibitor agent is administered via a route selected from the group consisting of intravenous administration, oral administration, and topical administration.